MEDIUMResearchTier 1
How drug may benefit patients with diabetes, cardiovascular disease
SourceAmerican Dental AssociationTier 1Hard News
Originally at news.google.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dentists managing patients with Type 2 diabetes and cardiovascular disease may see altered medication regimens that affect periodontal outcomes, glycemic control, and infection risk, potentially shifting treatment planning and recall intervals.
Key points
- Investigators analyzed national claims data from more than 50,000 adults aged 40 and older with Type 2 diabetes and established atherosclerotic cardiovascular disease.
- Patients receiving tirzepatide experienced a lower risk of major adverse cardiovascular events than those receiving sitagliptin.
- Tirzepatide use was linked to reduced likelihood of myocardial infarction and all-cause mortality, with no statistically significant difference in ischemic stroke.
- Patients on tirzepatide showed lower rates of infection-related hospitalization or mortality compared with sitagliptin users.
Who should care
AssociateSpecialistAcademia
Read the original on ADA News
Full reporting and any paywall content live on news.google.com. We summarize and score; we do not republish.